Boston Scientific Q1 sales $4.66B (+20.9% reported, +18.2% organic), EPS beat guidance

BOSTON SCIENTIFIC CORP

2025-Q1 EPS reported $0.45 revenue$4,663,000,000

GAAP EPS $0.45 (up 36% YoY); adjusted EPS $0.75, above guidance $0.66-0.68.
Cardiovascular segment sales grew 26.2% reported (25.6% organic); MedSurg +11.7% reported (+5.3% organic).
U.S. sales up 31.1%; EMEA +5.5%, APAC +8.2%, LACA +4.4%.
FY2025 outlook: organic +12-14%, adj. EPS $2.87-$2.94; Q2: organic +13-15%, adj. EPS $0.71-$0.73.
Closed Bolt Medical acquisition; agreed to acquire SoniVie Ltd. for TIVUS hypertension denervation technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.